Firefly Neuroscience Breakthrough Cognitive Brain Age Biomarker Uses FDA-Cleared BNA Platform

 

Measuring brain age with EEG and BNA™ could lead to a proactive and scalable approach to early screening for Alzheimer's patients

Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced the advancement of research to assess a patient’s brain age - an estimation of the biological age of a person's brain – via its FDA-cleared BNA™ technology platform.

https://www.globenewswire.com/news-release/2025/01/14/3009212/0/en/Firefly-Neuroscience-Discovers-Breakthrough-Cognitive-Brain-Age-Biomarker-Using-its-FDA-Cleared-BNA-Platform.html